🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPharmacology & MechanismsSemaglutide fatty acid sidechain — 12 month update

Semaglutide fatty acid sidechain — 12 month update

SaraMom3 Wed, Sep 11, 2024 at 3:09 PM 36 replies 2,367 viewsPage 1 of 8
This thread is more than 21 months old. Information may be outdated. Consider searching for more recent discussions.
SaraMom3
Member
456
2,345
Aug 2024
Ohio
Sep 11, 2024 at 3:09 PM#1

I have been on semaglutide for nine months, currently holding 1.7mg rather than pushing to 2.4mg, and the last two dose steps bought me much less than the first two did.

Worth knowing that the injection site changes very little. Abdomen, thigh and upper arm are bioequivalent for semaglutide, so a site change is not a plausible explanation for a bad week.

What I am after is whether anyone has held at a sub-maximal dose long term and kept the result, or whether the maintenance data only exists at 2.4mg.

I would rather have one careful answer than five confident ones.

9 4BethLabQueen, ChrisMacros, KetoKyle and 6 others
Reply Quote Save Share Report
LarryQC_SD
Senior Member
2,123
9,876
Jan 2024
San Diego, CA
Sep 11, 2024 at 5:36 PM#2

Taking the question as asked, rather than the general version of it. Steady state is the thing most people miss. The terminal half-life is about a week, so every dose step takes four to five weeks to fully express itself. Judging a step at day ten is judging the ascent, not the plateau, and it is the single commonest reason people escalate before they needed to.

Happy to go further on any of that.

8 3paul_denver, TinaHashiRN, robert_kc and 5 others
Reply Quote Save Share Report
pat_auckland
Member
345
1,567
Jun 2024
Auckland, NZ
Sep 11, 2024 at 8:03 PM#3
LarryQC_SD said:
Steady state is the thing most people miss.

LarryQC_SD has the substance of this right. The condition it depends on is worth stating. The mechanism that matters here is not stomach emptying, it is central. GLP-1 receptor agonism in the arcuate nucleus stimulates POMC neurons and suppresses AgRP/NPY signalling, which is why the effect is appetite and food salience rather than physical fullness. Delayed gastric emptying largely tachyphylaxes over the first months; the appetite effect does not.

7 2LarryQC_SD, wanda_boise, NurseAsh_DET and 4 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
sarah_nash92
Member
712
3,123
Jun 2024
Nashville, TN
Sep 11, 2024 at 10:30 PM#4
SaraMom3 said:
I have been on semaglutide for nine months, currently holding 1.7mg rather than pushing to 2.4mg, and the last two dose steps bought me much less than…

Agreed, though "tolerable" needs defining. A dose you tolerate by eating almost nothing is not tolerated, it is being paid for somewhere else — usually in lean mass, sometimes in adherence three months later.

6 1CanadaChris, ZaraB_AL, JakeSmashed95 and 3 others
Reply Quote Save Share Report
ingrid_STO
Member
345
1,456
Jul 2024
Stockholm, SE
Sep 12, 2024 at 1:13 PM#5

From the other side of the consultation, briefly.

SaraMom3 said:
...but the FDA says semaglutide...

Interesting point. I want to add some regulatory nuance: the FDA labeling reflects the specific clinical trial data submitted for approval. Real-world clinical practice often extends beyond the FDA label based on emerging evidence and clinical judgment.

Example: semaglutide was first approved for diabetes (Ozempic), then obesity (Wegovy). The molecule didn't change — our understanding of its applications expanded. Similarly, semaglutide may evolve as more data accumulates.

Last edited: Sep 12, 2024 at 4:13 PM
5 0WendyG_ATL, SaraMom3, Dr.MetabolicMD and 2 others
Reply Quote Save Share Report
1238

Similar Threads

GLP-1R desensitization — β-arrestin-mediated internalization18 replies
Biased agonism at GLP-1R — Gs vs β-arrestin signaling balance13 replies
Semaglutide albumin binding and the C-18 fatty acid linker17 replies
GIP receptor pharmacology — why GIP agonism enhances GLP-113 replies
Glucagon receptor signaling — hepatic glycogenolysis and lipolysis16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register